Editorial Commentary: More Clinical Trials Should Focus on Primary Prevention of Osteoarthritis: Disruptive Thinkers Are Required.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34353566.
- Also identified by DOI 10.1016/j.arthro.2021.05.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With increasing life expectancy and an increased prevalence of osteoarthritis, the total number of individuals with symptomatic degenerative arthritis will most likely increase considerably. The current focus of nonoperative treatment is on weight loss, exercise, muscle strengthening, physical therapy, nonsteroidal anti-inflammatory drugs, intra-articular injection therapies with corticosteroids, hyaluronic acid, or platelet-rich plasma, and lately, disease-modifying drugs. Obviously, prevention is better than cure, but only 5% of all studies registered on ClinicalTrials.gov in the United States are intending to develop strategies for prevention. The overall majority of included studies (89%) will target symptom resolution, and 6% will investigate disease-modifying drugs.
Medical subject headings
- Osteoarthritis, Knee
- Platelet-Rich Plasma
Anatomy
- knee